Showing 1 to 4 of 4 results
Discovery of Key Cells Causing Axial Spondyloarthritis Opens Door to New Treatments
Oxford University researchers discovered that trapped CD4+ TRM17 cells in joints produce the inflammatory protein IL-17, causing axial spondyloarthritis (SpA) in approximately 200,000 people in the UK, potentially leading to new treatments targeting these cells.
Discovery of Key Cells Causing Axial Spondyloarthritis Opens Door to New Treatments
Oxford University researchers discovered that trapped CD4+ TRM17 cells in joints produce the inflammatory protein IL-17, causing axial spondyloarthritis (SpA) in approximately 200,000 people in the UK, potentially leading to new treatments targeting these cells.
Progress
36% Bias Score
New Antibiotic Gepotidacin Shows Promise Against Rising Gonorrhea Cases
The FDA approved gepotidacin, a new antibiotic effective against urinary tract infections and gonorrhea; a phase III trial showed it's as effective as the standard treatment for gonorrhea, a sexually transmitted infection with rising antibiotic resistance, nearly doubling in Spain between 2021 and 2...
New Antibiotic Gepotidacin Shows Promise Against Rising Gonorrhea Cases
The FDA approved gepotidacin, a new antibiotic effective against urinary tract infections and gonorrhea; a phase III trial showed it's as effective as the standard treatment for gonorrhea, a sexually transmitted infection with rising antibiotic resistance, nearly doubling in Spain between 2021 and 2...
Progress
48% Bias Score
New Bladder Cancer Treatment Offers Hope in Australia
A new combined chemotherapy treatment for bladder cancer is being rolled out in Australian hospitals, offering a significant improvement in survival rates for patients with aggressive cancers in the lining of the bladder who are unsuitable for surgery or immunotherapy, with a 60-69% success rate rep...
New Bladder Cancer Treatment Offers Hope in Australia
A new combined chemotherapy treatment for bladder cancer is being rolled out in Australian hospitals, offering a significant improvement in survival rates for patients with aggressive cancers in the lining of the bladder who are unsuitable for surgery or immunotherapy, with a 60-69% success rate rep...
Progress
40% Bias Score
New Asthma Attack Drug Shows Promise
Researchers report Benralizumab, a new drug, is more effective than steroids in treating severe asthma attacks; targeting eosinophils, it showed significantly lower treatment failure rates (45% vs 74%) in a 158-person clinical trial, leading to fewer hospitalizations and improved patient outcomes.
New Asthma Attack Drug Shows Promise
Researchers report Benralizumab, a new drug, is more effective than steroids in treating severe asthma attacks; targeting eosinophils, it showed significantly lower treatment failure rates (45% vs 74%) in a 158-person clinical trial, leading to fewer hospitalizations and improved patient outcomes.
Progress
40% Bias Score
Showing 1 to 4 of 4 results